Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants

Université de Montréal

$60,000.00

Role of ARF1 as a key GTPAse regulating immune surveillance in breast cancer

EF 2020-21

Résumé
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with an overall poor clinical outcome. Reports have demonstrated that the unique microenvironment in which tumor cells grow (suppressive immune cells, altered extracellular matrix and soluble mitogenic factors) contributes to further promote cancer progression. In our effort to identify key molecular switch that control progression of TNBC, we have uncovered that the small G protein ARF1 (ADP-ribosylation factor) is overexpressed and act as a key regulator of the signaling cascades that control cell migration, invasion and proliferation. When ARF1 is knocked down, the ability of triple-negative tumor cells to proliferate and form metastasis in animal models is markedly impaired. Our most recent findings supporting this project grant suggest that ARF1 regulates the ability of TNBC cells to release factors such as pro-inflammatory cytokines like IL-6, but also expression of immune checkpoint ligands such as PD-L1, to control immune cell infiltration and ultimately immune bypass. Together, these results suggest that ARF may be a key protein, expressed in TNBC cells, that not only contribute to tumorigenesis and metastasis by regulating alterations of signaling cascades regulating key physiological features of tumor cells, but other factors that are known to control the nature of the unique microenvironment that support tumor cells growth and cancer progression. HYPOTHESIS & AIMS Our main hypothesis is that high ARF1 expression confers tumor cells advantages by modulating the signals they send to the immune system to escape surveillance. We therefore propose: 1) Define the role of ARF1 on the secretion of cytokines associated with the modulation of the immune response and the expression of checkpoint molecule ligands important for immune bypass. We will assess whether modulation of ARF1 expression or activity affect secretion of IL-6 and other cytokines, by TNBC cells, known to regulate tumor growth. We will also define the underlying molecular mechanisms by examining signaling events and activation of transcription factors. We will determine whether ARF1 expression or activation control transcription of the PD-L1 gene (cd274) in TNBC cells, and test if this GTPase can act to control stability of PD-L1 protein knowing that post-translational modifications are important for function. 2) Define the role of ARF1 in the recruitment of tumor growth promoting immune cells in the tumor microenvironment. We will use in vitro assays (cell culture and co-culture) and pre-clinical animal models (syngeneic and humanized) to examine the role high ARF1 expression plays on the ability of TNBC cells to regulate the recruitment of Tumor Infiltrating Macrophages and lymphocytes. The sygeneic murine model will provide key information regarding the context of an intact immune system, while the human TNBC cells transplanted in humanized mice will allow extrapolating our findings to the clinical context of breast cancer progression in patients. Insights gained from the proposed research project will greatly contribute to elucidate the underlying mechanisms of ARF1, on the immune system, to promote tumor growth and cancer progression. Because current TNBC therapies are only partially effective, we must continue to search for new molecular targets in order to improve current immunotherapies or find new one so we can optimize treatment strategies for TNBC patients. All our work suggest that ARF1 is a potential new pharmacological target because of its central role in invasive breast tumor progression.
Programme
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
453489
Name
Claing Audrey
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Role of ARF1 as a key GTPAse regulating immune surveillance in breast cancer
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Immunotherapy; Metastasis; Targets And Biomarkers
Abstract
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with an overall poor clinical outcome. Reports have demonstrated that the unique microenvironment in which tumor cells grow (suppressive immune cells, altered extracellular matrix and soluble mitogenic factors) contributes to further promote cancer progression. In our effort to identify key molecular switch that control progression of TNBC, we have uncovered that the small G protein ARF1 (ADP-ribosylation factor) is overexpressed and act as a key regulator of the signaling cascades that control cell migration, invasion and proliferation. When ARF1 is knocked down, the ability of triple-negative tumor cells to proliferate and form metastasis in animal models is markedly impaired. Our most recent findings supporting this project grant suggest that ARF1 regulates the ability of TNBC cells to release factors such as pro-inflammatory cytokines like IL-6, but also expression of immune checkpoint ligands such as PD-L1, to control immune cell infiltration and ultimately immune bypass. Together, these results suggest that ARF may be a key protein, expressed in TNBC cells, that not only contribute to tumorigenesis and metastasis by regulating alterations of signaling cascades regulating key physiological features of tumor cells, but other factors that are known to control the nature of the unique microenvironment that support tumor cells growth and cancer progression. HYPOTHESIS & AIMS Our main hypothesis is that high ARF1 expression confers tumor cells advantages by modulating the signals they send to the immune system to escape surveillance. We therefore propose: 1) Define the role of ARF1 on the secretion of cytokines associated with the modulation of the immune response and the expression of checkpoint molecule ligands important for immune bypass. We will assess whether modulation of ARF1 expression or activity affect secretion of IL-6 and other cytokines, by TNBC cells, known to regulate tumor growth. We will also define the underlying molecular mechanisms by examining signaling events and activation of transcription factors. We will determine whether ARF1 expression or activation control transcription of the PD-L1 gene (cd274) in TNBC cells, and test if this GTPase can act to control stability of PD-L1 protein knowing that post-translational modifications are important for function. 2) Define the role of ARF1 in the recruitment of tumor growth promoting immune cells in the tumor microenvironment. We will use in vitro assays (cell culture and co-culture) and pre-clinical animal models (syngeneic and humanized) to examine the role high ARF1 expression plays on the ability of TNBC cells to regulate the recruitment of Tumor Infiltrating Macrophages and lymphocytes. The sygeneic murine model will provide key information regarding the context of an intact immune system, while the human TNBC cells transplanted in humanized mice will allow extrapolating our findings to the clinical context of breast cancer progression in patients. Insights gained from the proposed research project will greatly contribute to elucidate the underlying mechanisms of ARF1, on the immune system, to promote tumor growth and cancer progression. Because current TNBC therapies are only partially effective, we must continue to search for new molecular targets in order to improve current immunotherapies or find new one so we can optimize treatment strategies for TNBC patients. All our work suggest that ARF1 is a potential new pharmacological target because of its central role in invasive breast tumor progression.
Competitiondate
202103
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Claing, Audrey
Approvedterm
2 ans 0 mois
Cihrcontribution2
Breast Cancer Initiative~ $60,000~ $0~